Catheter Precision, Inc. (NYSE American: VTAK) released its financials and highlights for the Second Quarter of 2023, unveiling total assets amounting to $35.5 million and cash reserves of $7.4 million and revenues for the six-month period ending on June 30, 2023.  Catheter Precision, Inc., is a U.S.-based medical device company, offering innovative solutions to enhance the treatment of cardiac arrhythmias. The company collaborates with physicians to develop cutting-edge technology for electrophysiology procedures, and it consistently focuses on enhancing its product offerings. 

Moreover, in the second quarter, Catheter Precision, Inc. initiated the inaugural LockeT study with the participation of 100 patients. This observational investigation aimed to demonstrate the viability of a cost-effective alternative to current closure methods. (LockeT serves as a suture retention device designed for wound healing. It distributes suture tension across a larger area in conjunction with a figure-of-eight suture closure, temporarily securing sutures). 

Additionally, another noteworthy achievement includes the successful enrolment of 125 patients in the VIVO™ patient registry. Follow-up data for these registered patients is anticipated to be disclosed in mid-2024. (VIVO™, or View into Ventricular Onset, is a non-invasive 3D imaging system that empowers physicians to identify the origin of arrhythmias before procedures, thereby streamlining workflow and reducing procedure time). A major milestone in the second quarter involved Catheter Precision's ongoing endeavours to establish crucial VIVO™ accounts in both Europe and the United States. The observational study, emphasizing a competitively priced alternative to prevalent closure methods, underscored the company's dedication to innovation and advancement. 

Furthermore, the company has effectively trained and assembled a sales team based in the United States. Another noteworthy development includes the successful onboarding and training of additional personnel in the United States, coupled with the enlistment of a consulting group to secure international contracts for the distribution of the LockeT product. Catheter Precision, Inc. remains dedicated to pursuing intellectual property filings for both LockeT and VIVO™. 

Presently, Catheter Precision, Inc.’s (NYSE American: VTAK) shares are fluctuating within a tight range above the 50-day moving average ($0.43), consolidating with positive indicators, and surpassing the 30-day average trading volume. This suggests a potential buying opportunity, hinting at a potential upward momentum. It is advisable to keep a close watch on this stock in the current period and the upcoming weeks.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com